Nipent (Pentostatin)

Pentostatin inhibits the enzyme adenosine deaminase, causing a buildup of deoxyadenosine nucleotides inside lymphocytes. This accumulation is toxic to the cells, leading to apoptosis of malignant B‑cells while sparing most other tissues.

The dosing regimen for pentostatin is individualized by the treating physician based on the patient’s weight, disease status, and laboratory parameters. Only a qualified prescriber can determine the appropriate dose and schedule.

Pentostatin is classified as contraindicated in pregnancy and lactation because it can cause fetal harm and is excreted in breast milk. Women of child‑bearing potential should use effective contraception and discuss alternatives with their healthcare provider.

To request Nipent, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The main alternative is cladribine, another purine analog. Both agents target the same enzymatic pathway, but pentostatin may be preferred in patients with specific renal or hepatic considerations, while cladribine is often given as a single course. Choice depends on individual patient factors and physician judgment.

Nipent must be stored refrigerated between 2 °C and 8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until ready for preparation and administration.

Nipent is supplied as a sterile injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a short infusion period, following aseptic technique and appropriate monitoring.

The most serious risks include profound immunosuppression leading to severe infections, hepatic toxicity, and rare but life‑threatening hypersensitivity reactions. Patients should be monitored closely for signs of infection, liver dysfunction, and allergic responses throughout therapy.

Nipent should not be used in patients with active severe infections, uncontrolled hepatic or renal impairment, known hypersensitivity to pentostatin or any excipients, or in pregnant or breastfeeding women. It is also contraindicated in individuals receiving live vaccines during treatment.